Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UFH · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| UFH | DRUG | Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds |
| Rivaroxaban (Xarelto, BAY59-7939) | DRUG | 10 mg single dose Rivaroxaban (per os) |
| Rivaroxaban (Xarelto, BAY59-7939) and UFH | DRUG | 10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH) |
Inclusion Criteria: * Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol * Symptomatic coronary artery disease due to undergo an elective (non-emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary ve...
UFH is an investigational small molecule being developed by Bayer AG for cardiovascular disease. It is currently in Phase 2 clinical development. UFH is being studied for its potential role in treating conditions related to cardiovascular disease, including coronary artery disease.
UFH is being investigated for use in cardiovascular disease, specifically in the context of elective percutaneous coronary intervention. A Phase 2 clinical trial explored its efficacy and safety in patients with cardiovascular disease and coronary artery disease, with the aim of supporting the procedure.
UFH is being developed by Bayer AG, a pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The company is conducting clinical research to evaluate UFH as a potential treatment for cardiovascular disease.
UFH is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an active-controlled, randomized study. The drug is still investigational and has not yet been approved for any use.
UFH has been studied in one clinical trial, identified as NCT01442792. This Phase 2 trial, titled 'Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention,' was completed and enrolled 108 participants with cardiovascular disease and coronary artery disease.
UFH is not the same as rivaroxaban. The clinical trial NCT01442792, which studied UFH, was titled with a reference to rivaroxaban, but UFH is a distinct investigational drug. The trial compared UFH against an active control, but the specific identity of UFH is separate from rivaroxaban.